70 results
8-K
EX-99.1
VRNA
Verona Pharma Plc
29 Feb 24
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
6:08am
and, subject to clearance, initiate a Phase 2 clinical trial assessing the safety and efficacy of the fixed-dose combination formulation in COPD … patients.
In the second half of 2024, the Company plans to commence a Phase 2 clinical trial to assess the efficacy and safety of nebulized ensifentrine
8-K
EX-99.1
hso4q7j
2 Nov 23
Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update
6:24am
8-K
EX-99.1
nhf1qy
3 Aug 23
Verona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update
6:11am
8-K
EX-99.1
fvdnttggw77w0649xzp
9 May 23
Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
6:13am
8-K
hntu9 1myu
20 Dec 22
Regulation FD Disclosure
6:02am
8-K
EX-99.1
9ovn 7vrltmx3hhv7o1
20 Dec 22
Regulation FD Disclosure
6:02am
8-K
EX-99.1
pq2iyxss05et80jr0t70
9 Nov 22
Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update
6:35am
424B5
q8ilec3k4864 hmy3
11 Aug 22
Prospectus supplement for primary offering
5:09pm
8-K
EX-99.2
mvs0aub5
9 Aug 22
Verona Pharma Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8:17am
8-K
EX-99.1
tbdu1y9508 c43tv
9 Aug 22
Verona Pharma Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8:17am
8-K
3e2yp5u bxq9
9 Aug 22
Verona Pharma Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8:17am
424B5
zusso
9 Aug 22
Prospectus supplement for primary offering
12:00am